68Ga DOTATOC PET
Ezziddin S et al: Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med 37: e141–e147, 2012.
Howard S et al: Multimodality imaging in amyloidosis. Cancer Imaging 12: 109–117, 2012.
Gelosa G et al: The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging 39: 1207–1219, 2012.
Mankia SK et al: The response of HIV-associated lymphadenopathic Kaposi sarcoma to highly active antiretroviral therapy evaluated by 18F-FDG PET/CT. Clin Nucl Med 37: 692–693, 2012.
Papathanasiou ND et al: F-18-fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol 85: e188–e194, 2012.
Folke Pedersen S et al: Microvessel density but not neoangiogenesis is associated with F-18-FDG uptake in human atherosclerotic carotid plaques. Mol Imaging 14: 384–392, 2012.
Song H-J et al: Percutaneous osteoplasty combined with radioiodine therapy as a treatment for bone metastasis developing after differentiated thyroid carcinoma. Clin Nucl Med 37: e129–e133, 2012.
Singh H et al: Schmorl’s node mimicking metastasis in a patient with breast cancer: diagnosis with 99mTc methylene diphosphonate SPECT-CT. Clin Nucl Med 37: 674–675, 2012.
Yoo SW et al: Herniation pit mimicking osseous metastasis on 18F-FDG PET/CT in patient with lung cancer. Clin Nucl Med 37: 682–683, 2012.
Samarin A et al: PET/MR imaging of bone lesions—implications for PET quantification from imperfect attenuation correction. Eur J Nucl Med Mol Imaging 39: 1154–1160, 2012.
Miot-Noirault E et al: In vivo experimental imaging of osteochondral defects and their healing using Tc-99m NTP 15-5 radiotracer. Eur J Nucl Med Mol Imaging 39: 1169–1172, 2012.
Luyx D et al: Skin lesions, elevated serum lipase level and abnormal bone scintigraphy. Eur J Nucl Med Mol Imaging 39: 1223–1224, 2012.
Patient guide to osteoporosis in men. J Clin Endocrinol Metab 97: 39A–40A, 2012.
Watts NB et al: Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 97: 1802–1822, 2012.
Drake MT et al: Risk factors for low bone mass–related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 97: 1861–1870, 2012.
Anderson WJ et al: Prospective follow-up of novel markers of bone turnover in persistent asthmatics exposed to low and high doses of inhaled ciclesonide over 12 months. J Clin Endocrinol Metab 97: 1929–1936, 2012.
Young Kim H et al: The changes in plasma serotonin levels after hormone therapy and their relationship with estrogen responsiveness on bone in postmenopausal women. J Clin Endocrinol Metab 97: 1986–1994, 2012.
Soo Lim J et al: Gender-dependent skeletal effects of vitamin D deficiency in a younger generation. J Clin Endocrinol Metab 97: 1995–2004, 2012.
Neyestani TR et al: Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes. J Clin Endocrinol Metab 97: 2005–2011, 2012.
Arasu A et al: Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 97: 2027–2032, 2012.
Lawlor DA et al: The association of fasting insulin, glucose, and lipids with bone mass in adolescents: findings from a cross-sectional study. J Clin Endocrinol Metab 97: 2068–2076, 2012.
Komissarova M et al: F-18-FDG PET/CT and Tc-99m-MDP imaging of non–small cell lung carcinoma osseous metastases. J Nucl Med Technol 40: 66–67, 2012.
Whitaker M et al: Bisphosphonates for osteoporosis—where do we go from here? N Engl J Med 366: 2045–2051, 2012.
Black DM et al: Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med 366: 2051–2053, 2012.
Nagarajah J et al: 18F-fluoride PET/CT for bone scanning. Role of attenuation correction. Nuklearmedizin 51: 84–87, 2012. (German)
Dobrindt O et al: MRI versus bone scintigraphy. Evaluation for diagnosis and grading of stress injuries. Nuklearmedizin 51: 88–94, 2012. (German)
Sabet A et al: Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy. Nuklearmedizin 51: 95–100, 2012. (German)
Puri T et al: Comparison of six quantitative methods for the measurement of bone turnover at the hip and lumbar spine using 18F-fluoride PET-CT. Nucl Med Commun 33: 597–606, 2012.
Saboury B et al: Promising roles of PET in management or arthroplasty-associated infection. PET Clin 7: 139–150, 2012.
Dioguardi P et al: FDG PET assessment of osteomyelitis: a review. PET Clin 7: 161–179, 2012.
Beck BR et al: Tibial stress injury: relationship of radiographic, nuclear medicine bone scanning, MR imaging, and CT severity grades to clinical severity and time to healing. Radiology 263: 811–818, 2012.
Kotsenas AL: Imaging of posterior element axial pain generators: facet joints, pedicles, spinous processes, sarcroiliac joints, and transitional segments. Radiol Clin North Am 50: 705–730, 2012.
Zaman K et al: Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 23: 1474–1481, 2012.
Bolland MJ et al: Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab 97: 1922–1928, 2012.
Curtis JR et al: Association of intact parathyroid hormone levels with subsequent hip BMD loss: the osteoporotic fractures in men (MrOS) study. J Clin Endocrinol Metab 97: 1937–1944, 2012.
Crandall CJ et al: Socioeconomic status over the life-course and adult bone mineral density: the midlife in the U.S. Bone 51: 107–113, 2012.
Tjhia CK et al: Relating micromechanical properties and mineral densities in severely suppressed bone turnover patients, osteoporotic patients, and normal subjects. Bone 51: 114–122, 2012.
Maple-Brown LJ et al: Increased bone mineral density in Aboriginal and Torres Strait Islander Australians: impact of body composition. Bone 51: 123–130, 2012.
Murthy NS: Imaging of stress fractures of the spine. Radiol Clin North Am 50: 799–821, 2012.
Contrafatto D et al: 123FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism. Acta Neurol Scand 126: 12–16, 2012.
Willowson K et al: CT-based quantitative SPECT for the radionuclide Tl-201: experimental validation and a standardized uptake value for brain tumour patients. Cancer Imaging 12: 31–40, 2012.
Alexiou GA et al: The role of 99mTc-tetrofosmin brain SPECT in intracranial meningiomas. Clin Nucl Med 37: 583, 2012.
Lee SJ et al: Apparent relative hypermetabolism of selective brain areas in Huntington disease and importance of reference region for analysis. Clin Nucl Med 37: 663–668, 2012.
Heinzel A et al: Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging 39: 1089–1096, 2012.
Newberg AB et al: Initial clinical comparison of F-18-florbetapir and F-18-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 53: 902–907, 2012.
Lemoine L et al: Radiosynthesis and preclinical evaluation of F-18-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging. J Nucl Med 53: 969–976, 2012.
Strauss LG et al: Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging 14: 376–383, 2012.
Protas HD et al: Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET. Neuroimage 61: 749–760, 2012.
Colavolpe C et al: FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan. Neuro Oncol 14: 649–657, 2012.
Calabria F et al: Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. Nucl Med Commun 33: 563–570, 2012.
Farid K et al: Brain perfusion SPECT imaging and acetazolamide challenge in vascular cognitive impairment. Nucl Med Commun 33: 571–580, 2012.
Yamamoto Y et al: Hypoxia assessed by 18F-fluoromisonidazole positron emission tomography in newly diagnosed gliomas. Nucl Med Commun 33: 621–625, 2012.
Katayama T et al: Evaluation of sequential FDG-PET/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers. Ann Nucl Med 26: 426–435, 2012.
Tadwalkar RV et al: Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade. Br J Radiol 85: e212–e216, 2012.
Abhyankar A et al: FDG uptake in unilateral breast related to breastfeeding practice in a patient of pulmonary hyadatid cyst. Clin Nucl Med 37: 676-678, 2012.
Brouwer OR et al: Lymphoscintigraphy and SPECT/CT in multicentric and multifocal breast cancer: does each tumour have a separate drainage pattern? Results of a Dutch multicentre study (MULTISENT). Eur J Nucl Med Mol Imaging 39: 1137–1143, 2012.
Hindié E et al: Lymphoscintigraphy can select breast cancer patients for internal mammary chain. Int J Radiat Oncol Biol Phys 83: 1081–1088, 2012.
Prekeges J: Breast imaging devices for the nuclear medicine. J Nucl Med Technol 40: 71–78, 2012.
Manohar K et al: Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 33: 591–596, 2012.
Brown Adipose Tissue
Skillen A et al: Thermal control of brown adipose tissue in F-18-FDG PET. J Nucl Med Technol 40: 99–103, 2012.
Cronin CG et al: Brown fat at PET/CT: correlation with patient characteristics. Radiology 263: 836–842, 2012.
Kadanali A et al: Detection of orchitis and sacroiliitis due to brucellosis by 99mTc polyclonal human immunoglobulin scintigraphy. Clin Nucl Med 37: 671–673, 2012.
C-13 MR Spectroscopic Imaging
Brindle K: Watching tumours gasp and die with MRI: the promise of hyperpolarised C-13 MR spectroscopic imaging. Br J Radiol 85: 697–708, 2012.
Manabe O et al: Multimodality evaluation of cardiac paraganglioma. Clin Nucl Med 37: 599–601, 2012.
Leva L et al: The relationship between quantitative perfusion and functional results and acquisition time with reduced administered activity for 99mTc tetrofosmin myocardial gated-SPECT. Clin Nucl Med 37: e162–e169, 2012.
Franceschi AM et al: Four chamber FDG uptake in the heart: an indirect sign of pulmonary embolism. Clin Nucl Med 37: 687–691, 2012.
Chen C et al: LV dyssynchrony as assessed by phase analysis of gated SPECT myocardial perfusion imaging in patients with Wolff-Parkinson-White syndrome. Eur J Nucl Med Mol Imaging 39: 1191–1198, 2012.
Marciano C et al: Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. Eur J Nucl Med Mol Imaging 39: 1199–1206, 2012.
Rahbar K et al: Differentiation of malignant and benign cardiac tumors using F-18-FDG PET/CT. J Nucl Med 53: 856–863, 2012.
Fukushima K et al: Impaired global myocardial flow dynamics despite normal left ventricular function and regional perfusion in chronic kidney disease: a quantitative analysis of clinical Rb-82 PET/CT studies. J Nucl Med 53: 887–893, 2012.
Tian J et al: Integration of 3-dimensional scar models from SPECT to guide ventricular tachycardia ablation. J Nucl Med 53: 894–901, 2012.
Lyall A et al: Treadmill exercise inducing mild to moderate ischemia has no significant effect on skeletal muscle or cardiac F-18-FDG uptake and image quality on subsequent whole-body PET scan. J Nucl Med 53: 917–921, 2012.
Chand Kheruka S et al: An investigation of a sinogram discontinuity artifact on myocardial perfusion imaging. J Nucl Med Technol 40: 25–28, 2012.
Duarte DD et al: Influence of reconstruction parameters during filtered backprojection and ordered-subset expectation maximization in the measurement of the left-ventricular volumes and function during gated SPECT. J Nucl Med Technol 40: 29–36, 2012.
Thériault Lauzier P et al: Noise spatial nonuniformity and the impact of statistical image reconstruction in CT myocardial perfusion imaging. Med Phys 39: 4079, 2012.
Hung M-C et al: Myocardial perfusion scintigraphy in Taiwan from 2005–2009, 2012. Nucl Med Commun 33: 733–738, 2012.
Celik F et al: Clinical significance of regional F-18-FDG myocardial uptake. Tijdschr NG 34: 836–849, 2012. (Dutch)
Rose BS et al: Correlation between radiation dose to F-18-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 83: 1185–1191, 2012.
Arai H et al: SPECT/CT imaging in radionuclide cisternography to detect cerebrospinal fluid leakage in spontaneous intracranial hypotension associated with SLE. Eur J Nucl Med Mol Imaging 39: 1225–1226, 2012.
Khorshidi A et al: Estimation of fan beam and parallel beam parameters in a wire mesh design. J Nucl Med Technol 40: 37–43, 2012.
Communicating in Organizations
Harolds JA: Communicating in organizations, Part IV: e-mails and one-on-one meetings. Clin Nucl Med 37: 580–582, 2012.
Bhatt MK et al: FDG PET/CT appearance of benign pilomatricoma. Clin Nucl Med 37: 684–686, 2012.
Kaplan RC et al: Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. J Clin Endocrinol Metab 97: 1970–1976, 2012.
Azhadarinia A et al: Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis. Mol Imaging 14: 261–276, 2012.
Dual Point FDG Imaging
Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med 42: 267–280, 2012.
Ehramamci S et al: The clinical value and histopathological correlation of lacrimal scintigraphy in patients with primary Sjögren’s syndrome. Nucl Med Commun 33: 689–694, 2012.
Fever of Unknown Origin
Yang J et al: Fever of unknown origin: the roles of FDG PET or PET/CT. PET Clin 7: 181–189, 2012.
Full Body FDG PET/CT Scans
Bauer C et al: Automated measurement of uptake in cerebellum, liver, and aortic arch in full-body FDG PET/CT scans. Med Phys 39: 3112–3123, 2012.
Oh J-R et al: A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT. Clin Nucl Med 37: e134–e140, 2012.
Wells IT et al: PET/CT in anal cancer—is it worth doing? Clin Radiol 67: 535–540, 2012.
Chul Park J et al: Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging 39: 1107–1116, 2012.
Fin L et al: Improved imaging of intrahepatic colorectal metastasis with 18F-fluorodeoxyglucose respiratory-gated positron emission tomography. Nucl Med Commun 33: 656–662, 2012.
Zafar HM et al: Predictors of initial 18F-fluorodeoxyglucose–positron emission tomography indication among patients with colorectal cancer. Nucl Med Commun 33: 739–746, 2012.
Hustinx R: The utility of FDG PET/CT in inflammatory bowel disease. PET Clin 7: 219–225, 2012.
Rockall AG et al: The role of FDG-PET/CT in gynaecological cancers. Cancer Imaging 12: 49–65, 2012.
Jadvar H et al: Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med 37: 637–643, 2012.
Sharma P et al: Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 37: 649–655, 2012.
Lee JH et al: Inflammatory pseudotumor of the kidney mimicking malignancy on 18F-FDG PET/CT in a patient with diabetes and hepatocellular carcinoma. Clin Nucl Med 37: 699–701, 2012.
Welling RD et al: Extrarenal retroperitoneal angiomyolipoma mimicking metastatic melanoma: CT and FDG PET correlation. Clin Nucl Med 37: 705–706, 2012.
Sakhaee K et al: Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97: 1847–1860, 2012.
Lee EE et al: ACTH and cortisol response to Dex/CRH testing in women with and without premenstrual dysphoria during GnRH agonist–induced hypogonadism and ovarian steroid replacement. J Clin Endocrinol Metab 97: 1887–1896, 2012.
Herbert C et al: Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: a population-based cohort study. Radiother Oncol 103: 228–232, 2012.
Khandani AH et al: Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med 42: 221–230, 2012.
Ting Lee S et al: PET in prostate and bladder tumors. Semin Nucl Med 42: 231–246, 2012.
Arkies H et al: Retrospective analysis F-18-FDG PET/CT in cervical cancer compared to MRI. Tijdschr NG 34: 863–864, 2012. (Dutch)
Head and Neck
Minamimoto R et al: Reevaluation of FDG-PET/CT in patients with hoarseness caused by vocal cord palsy. Ann Nucl Med 26: 405–411, 2012.
van den Berg NS et al: Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-Tc-99m-nanocolloid. Eur J Nucl Med Mol Imaging 39: 1128–1136, 2012.
Young Kim J et al: Diagnostic value of neck node status using F-18-FDG PET for salivary duct carcinoma of the major salivary glands. J Nucl Med 53: 881–886, 2012.
Beswick DM et al: Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring. Layrngoscope 122: 1512–1517, 2012.
Amrein K et al: A challenging case of hypocalcemia supporting the concept that 25-hydroxyvitamin D status is important for intestinal calcium absorption. J Clin Endocrinol Metab 97: 1842–1846, 2012.
Petrik M et al: Preclinical evaluation of two Ga-68-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging. Eur J Nucl Med Mol Imaging 39: 1175–1183, 2012.
Sathekge M et al: Tuberculous lymphadenitis: FDG PET and CT findings in responsive and nonresponsive disease. Eur J Nucl Med Mol Imaging 39: 1184–1190, 2012.
Sathekge M et al: Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals. Nucl Med Commun 33: 581–590, 2012.
Alavi A et al: PET imaging of infection and inflammation. PET Clin 7: xi, 2012.
Basu S et al: FDG PET and PET/CT imaging in complicated diabetic foot. PET Clin 7: 151–160, 2012.
Palestro CJ et al: Decreased sensitivity of F-18-fluorodeoxyglucose imaging in infection and inflammation. Semin Nucl Med 42: 261–266, 2012.
Hu X et al: F-18 FDG PET/CT imaging of solitary liver Langerhans cell histiocytosis: preliminary findings. Ann Nucl Med 26: 436–439, 2012.
Karaman B et al: Complete disappearance of uptake of FDG in the multifocal liver hemangioendothelioma after radioembolization therapy using yttrium-90 microspheres. Ann Nucl Med 26: 440–443, 2012.
Tulchinsky M et al: Mebrofenin clearance rate for liver function testing: standardization of methodology aimed to improve intraobserver reproducibility. Clin Nucl Med 37: 649–655, 2012.
Sanli Y et al: Hepatic adenomatosis may mimic metastatic lesions of liver with 18F-FDG PET/CT. Clin Nucl Med 37: 697–698, 2012.
Sogawa C et al: Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma. Nucl Med Commun 33: 719–725, 2012.
Fartoux L et al: A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nucl Med Commun 33: 757–765, 2012.
Sheh SH et al: Pulmonary embolism diagnosis and mortality with pulmonary CT angiography versus ventilation-perfusion scintigraphy: evidence of overdiagnosis with CT? AJR Am J Roentgenol 198: 1340–1345, 2012.
Wagner T et al: Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs. Cancer Imaging 12: 7–12, 2012.
Hauber H-P et al: Positron emission tomography in the staging of small-cell lung cancer. A preliminary study. Chest 119: 950–954, 2012.
Shen DHY et al: Conversion from FDG-negative to -positive during follow-up in a rare case of pulmonary lymphoepithelioma-like carcinoma. Clin Nucl Med 37: 679–681, 2012.
Gorospe L: Giant benign solitary fibrous tumor of the pleura: PET/CT findings. Clin Nucl Med 37: 702–704, 2012.
Scarsbrook AF: Up-front staging of suspected lung cancer with PET-CT—new horizon or false dawn? Clin Radiol 67: 521–522, 2012.
Kobe C et al: Predictive value of early and late residual F-18-fluorodeoxyglucose and F-18-fluorothymidine uptake using different SUV measurements in patients with non–small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging 39: 1117–1127, 2012.
Na Kim Y et al: A proposal for combined MRI and PET/CT interpretation criteria for preoperative nodal staging in non–small-cell lung cancer. Eur Radiol 22: 1537–1546, 2012.
Min Lee S et al: Accuracy and predictive features of FDG-PET/CT and CT for diagnosis of lymph node metastasis of T1 non–small-cell lung cancer manifesting as a subsolid nodule. Eur Radiol 22: 1556–1563, 2012.
Rao Bollineni V et al: Residual F-18-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non–small-cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 83: e551–e555, 2012.
Marshall HR et al: Variable lung density consideration in attenuation correction of whole-body PET/MRI. J Nucl Med 53: 977–984, 2012.
Parker JA et al: SNM Practice Guideline for Lung Scintigraphy 4.0. J Nucl Med Technol 40: 57–65, 2012.
Gill BS et al: The role of positron emission tomography following radiosurgical treatment of malignant lung lesions. Nucl Med Commun 33: 607–612, 2012.
Kim K et al: Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non–small-cell lung cancer. Nucl Med Commun 33: 613–620, 2012.
Smith J et al: Histogram matching for the generation of ventilation-perfusion difference images in SPECT lung scanning: a phantom study. Med Phys 39: 3026–3030, 2012.
Erasmus JJ et al: Low-sensitivity FDG-PET studies: less common lung neoplasms. Semin Nucl Med 42: 255–260, 2012.
Bache I et al: In vivo selection of non–small cell lung cancer patients with activating mutations in the epidermal growth factor receptor using C-11-erlotinib and positron emission tomography. Tijdschr NG 34: 860, 2012. (Dutch)
Van der Pas VR et al: Benign pulmonary lesions found by F-18-FDG PET/CT in a fast tract assessment of suspected lung cancer. Tijdschr NG 34: 860–861, 2012. (Dutch)
Meijer TWH et al: Differences in metabolism between adeno- and squamous cell non–small cell lung carcinomas according to GLUT1 and MCT4 expression. Tijdschr NG 34: 861: 2012. (Dutch)
Stamp GFW et al: Peripheral lymphovenous communication in lymphoedema. Nucl Med Commun 33: 701-707, 2012.
Maloney DG: Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366: 2008–2016, 2012.
Notohamiprodjo M et al: MR lymphangiography at 3.0 T: correlation with lymphoscintigraphy. Radiology 264: 78–87, 2012.
Gagnon C et al: Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab 97: 1953–1961, 2012.
Margulis AR: Molecular imaging: love it or lose it. Radiology 264: 5, 2012.
Rust E et al: Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging 12: 173–184, 2012.
Jadvar H: Hepatocellular carcinoma and gastroenteropancreatic neuroendocrine tumors: potential role of other positron emission tomography radiotracers. Semin Nucl Med 42: 247–254, 2012.
Miles K: Nuclear oncology in Cancer Imaging 2011. Cancer Imaging 12: 185–186, 2012.
Nuclear Medicine Technology Programs
Winn JM: Directory of accredited nuclear medicine technology programs. J Nucl Med Technol 40: 12A–18A, 2012.
Rojas-Anaya H et al: Stakeholder perspectives on the use of positron emission tomography in phase III oncology trials in the UK. Nucl Med Commun 33: 626–632, 2012.
Li M et al: Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 97: 2033–2049, 2012.
D’Arienzo M et al: 90Y PET-based dosimetry after selective internal radiotherapy treatments. Nucl Med Commun 33: 633–640, 2012.
Drzezga A et al: First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53: 845–855, 2012.
Buchbender C et al: Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med 53: 928–938, 2012.
Yang J et al: Metastatic embryonic rhabdomyosarcoma to the pancreas presenting as acute pancreatitis detected by FDG PET/CT. Clin Nucl Med 37: 694–696, 2012.
Normandin MD et al: In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using F-18-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med 53: 908–916, 2012.
Treglia G et al: Diagnostic performance of F-18-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging 39: 1144–1153, 2012.
Taieb D et al: Parathyroid scintigraphy: when, how, why? A concise systematic review. Clin Nucl Med 37: 568–574, 2012.
Mapelli P et al: Incidental finding of parathyroid adenoma with 11C-choline PET/CT. Clin Nucl Med 37: 593–595, 2012.
Cook MI et al: An unusual ectopic location of a parathyroid carcinoma arising within the thyroid gland. J Clin Endocrinol Metab 97: 1829–1833, 2012.
Yavuz S et al: Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor. J Clin Endocrinol Metab 97: 1834–1841, 2012.
Caveny SA et al: Parathyroid imaging: the importance of dual-radiopharmaceutical simultaneous acquisition with Tc-99m-sestabmibi and I-123. J Nucl Med Technol 40: 104–110, 2012.
Greenspan BS et al: SNM Practice Guideline for Parathyroid Scintigraphy 4.0. J Nucl Med Technol 40: 111–118, 2012.
Nakatani K et al: Roles and limitations of FDG PET in pediatric non–Hodgkin lymphoma. Clin Nucl Med 37: 656–662, 2012.
Cheuk DKL et al: PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 39: 1097–1106, 2012.
Wildi-Runge S et al: A high prevalence of dual thyroid ectopy in congenital hypothyroidism: evidence for insufficient signaling gradients during embryonic thyroid migration or for the polyclonal nature of the thyroid gland? J Clin Endocrinol Metab 97: E978–E981, 2012.
Fahey FH et al: Minimizing and communicating radiation risk in pediatric nuclear medicine. J Nucl Med Technol 40: 13–24, 2012.
DiPoce J et al: Pediatric osteomyelitis: a scintigraphic case-based review. Radiographics 32: 865–878, 2012.
Soussan M et al: Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy. Eur Radiol 22: 1479–1487, 2012.
Ishii S et al: Pheochromocytoma in multiple endocrine neoplasia type 2A: positive 123I MIBG with negative CT and equivocal 131I MIBG imaging. Clin Nucl Med 37: 596–598, 2012.
Sane T et al: Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? J Clin Endocrinol Metab 97: 2084–2092, 2012.
Harolds JA: Tips for giving a memorable presentation, part I: the speaker as an educator. Clin Nucl Med 37: 669–670, 2012.
Bakht MK et al: Bremsstrahlung parameters of praseodymium-142 in different human tissues: a dosimetric perspective for Pr-142 radionuclide therapy. Ann Nucl Med 26: 412–418, 2012.
Andreeff M et al: Measurement of ocular lens ionizing radiation exposure after radioiodine therapy. Nuklearmedizin 51: 73–78, 2012. (German)
Erba PA et al: Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 53: 922–927, 2012.
Hindorf C et al: Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun 33: 726–732, 2012.
FDG approves F-18-florbetapir PET agent. J Nucl Med 53: 15N, 2012.
Beach TA et al: Ensuring safe and quality medication use in nuclear medicine: a collaborative team achieves compliance with medication management standards. J Nucl Med Technol 40: 1–10, 2012.
Martinez T et al: Formulation of F-18-FDG: pH adjustment of buffered solution. J Nucl Med Technol 40: 48–49, 2012.
Schreck GA et al: Sm-153-EDTMP appears to accumulate only trivially within peritoneal ascites. J Nucl Med Technol 40: 50–51, 2012.
Walters LR et al: Stability evaluation of F-18-FDG at high radioactive concentrations. J Nucl Med Technol 40: 52–56, 2012.
Verwer EE et al: Quantification of hypoxia using F-18-FAZA and PET. Tijdschr NG 34: 862–863, 2012. (Dutch)
Reducing Preimaging Anxiety
Vogel WV et al: Intervention to lower anxiety of F-18-FDG PET/CT patients by use of audiovisual imagery during the uptake phase before imaging. J Nucl Med Technol 40: 92–98, 2012.
Peterson TE et al: Advances in preclinical SPECT instrumentation. J Nucl Med 53: 841–844, 2012.
Lagerburg V et al: A comparison of different energy window subtraction methods to correct for scatter and downscatter in I-123 SPECT imaging. Nucl Med Commun 33: 708–718, 2012.
Hughes T et al: A multivendor phantom study comparing the image quality produced from three state-of-the-art SPECT-CT systems. Nucl Med Commun 33: 663–670, 2012.
Yu JQ et al: PET/CT in patients with sarcoidosis or IgG4 disease. PET Clin 7: 191–210, 2012.
Rakheja R et al: Correlating metabolic activity on F-18-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. AJR Am J Roentgenol 198: 1409–1416, 2012.
Heuveling DA et al: Nanocolloid albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. Eur J Nucl Med Mol Imaging 39: 1161–1168, 2012.
Chandler KJ et al: Effect of patient age, breast density, and topical anesthetic cream on perceived pain with sentinel lymph node scintigraphy. J Nucl Med Technol 40: 44–47, 2012.
Khandelwal AR et al: Skeletal muscle metastases on FDG PET/CT imaging. Clin Nucl Med 37: 575–579, 2012.
Wu FCW: Caveat emptor: does testosterone treatment reduce mortality in men? J Clin Endocrinol Metab 97: 1884–1886, 2012.
Kauppi JT et al: Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by [18F]FDG-PET/CT. Acta Oncol 51: 636–644, 2012.
Nakaminato S et al: Prevalence of esophageal cancer during the pretreatment of hypopharyngeal cancer patients: a case-control study. Acta Oncol 51: 645–652, 2012.
Benz MR et al: 3′-Deoxy-3′-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma. Cancer 118: 3135–3144, 2012.
Yanagawa M et al: Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med 53: 872–880, 2012.
Kumar R et al: Assessment of therapy response by FDG PET in infection and inflammation. PET Clin 7: 233–243, 2012.
Van Asperen EA et al: End of treatment FDG PET therapy response monitoring in malignant lymphoma patients; 2 case-reports: avoid “jumping to conclusions.” Tijdschr NG 34: 861–862, 2012. (Dutch)
Yama N et al: A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131–treated well-differentiated thyroid cancer to improve bed control shorten isolation periods. Ann Nucl Med 26: 390–396, 2012.
Putzer D et al: First thyroid experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Clin Nucl Med 37: 539–544, 2012.
Kendler DB et al: Preablation stimulated thyroglobulin is a good predictor of successful ablation in patients with differentiated thyroid cancer. Clin Nucl Med 37: 545–549, 2012.
Moura-Neto A et al: Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves’ disease. Clin Nucl Med 37: 550–554, 2012.
Menges M et al: 131I SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma. Clin Nucl Med 37: 555–560, 2012.
Kunawudhi A et al: Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan. Clin Nucl Med 37: 561–567, 2012.
González P et al: Endogenous thyroid-stimulating hormone and radioactive iodine uptake in normal subjects. Clin Nucl Med 37: 584–586, 2012.
Nascimento C et al: Thoracic 131I uptake after previous pneumonectomy in patients treated for differentiated thyroid cancer. Clin Nucl Med 37: 587–590, 2012.
Harisankar CNB et al: Hybrid SPECT/CT evaluation of dual ectopia of thyroid in the absence of orthopedic thyroid gland. Clin Nucl Med 37: 602–603, 2012.
Mathiopoulou L et al: 99mTc pertechnetate thyroid scan leads to serendipitous detection of metastatic thyroid cancer. Clin Nucl Med 37: 604–606, 2012.
Sung JY et al: Diagnostic accuracy of fine-needle aspiration versus core-needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. Eur Radiol 22: 1564–1572, 2012.
Joong Kim Y et al: Cystic versus predominantly cystic thyroid nodules: efficacy of ethanol ablation and analysis of related factors. Eur Radiol 22: 1573–1578, 2012.
Ping Loh T et al: Macro-thyrotropin: a case report and review of literature. J Clin Endocrinol Metab 97: 1823–1828, 2012.
Hassani Y et al: Fecundity in young adults treated early for congenital hypothyroidism is related to the initial severity of the disease: a longitudinal population-based cohort study. J Clin Endocrinol Metab 97: 1897–1904, 2012.
Yip L et al: Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 97: 1905–1912, 2012.
Xu L et al: Functional variations in the ATM gene and susceptibility to differentiated thyroid carcinoma. J Clin Endocrinol Metab 97: 1913–1921, 2012.
Poltukova E et al: Is age a risk factor for hypothyroidism in pregnancy? An analysis of 5223 pregnant women. J Clin Endocrinol Metab 97: 1945–1952, 2012.
Somwaru LL et al: The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metab 97: 1962–1969, 2012.
Williams F et al: Mild maternal thyroid dysfunction at delivery of infants born ≤34 weeks and neurodevelopment outcome at 5.5 years. J Clin Endocrinol Metab 97: 1977–1985, 2012.
Jonklaas J et al: The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab 97: E878–E887, 2012.
Vrachimis A et al: Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin 51: 65–66, 2012. (German)
Wong KK et al: How has the management of medullary thyroid carcinoma changed with the advent of 18F-FDG PET radiopharmaceuticals. Nucl Med Commun 33: 679–688, 2012.
Naswa N et al: Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun 33: 766–774, 2012.
Soussan M et al: Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun 33: 775–779, 2012.
Hezemans REL et al: Response to CHOP treatment in a case of unexpected detection of papillary thyroid carcinoma. Tijdschr NG 34: 844–845, 2012. (Dutch)
Maor MH: In regard to “Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.” (Int J Radiat Oncol Biol Phys 2012;82:83–89). Int J Radiat Oncol Biol Phys 83: 769, 2012.
Barber TW et al: F-18-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging on esophageal cancer: a prospective study with mature survival data. J Nucl Med 53: 864–871, 2012.
Si H et al: Abundant blood supply and low P-glycoprotein expression on dynamic Tc-99m-MIBI imaging predicted better chemotherapy sensitivity for a breast cancer patient: a case report. J Nucl Med Technol 40: 89–91, 2012.
Schaefer A et al: Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy. Nuklearmedizin 51: 101–110, 2012. (German)
Quon H et al: Predictive and prognostic role of functional imaging of head and neck squamous cell carcinoma. Semin Radiat Oncol 22: 220–232, 2012.
Hirata M et al: Synthesis and evaluation of radioiodinated phenoxyquinazoline and benzylaminoquinazoline derivatives as new EGF receptor tyrosine kinase imaging ligands for tumor diagnosis using SPECT. Ann Nucl Med 26: 381–389, 2012.
Dixon AK et al: Standardising measurement of tumour vascularity by imaging: recommendations for ultrasound, computed tomography, magnetic resonance imaging and positron emission tomography. Eur Radiol 22: 1427–1429, 2012.
Aboagye EO et al: Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. Eur Radiol 22: 1465–1478, 2012.
Xu B et al: Utilization of FDG PET/CT in the management of inflammation and infection in patients with malignancies. PET Clin 7: 211–218, 2012.
Cheebsumon P: Quantification and tumour delineation in PET. Tijdschr NG 34: 850, 2012. (Dutch)
Keen H et al: An evaluation of 2-deoxy-2-[F-18]fluoro-D-glucose and 3′-deoxy-3′-[F-18]-fluorothymidine uptake in human tumor xenograft models. Mol Imaging 14: 355–365, 2012.
von Guggenberg E et al: Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies. Mol Imaging 14: 366–375, 2012.
Use Criteria in Nuclear Medicine
Farrell MB et al: Understanding appropriate use criteria in nuclear medicine. J Nucl Med Technol 40: 81–86, 2012.
Cao Q et al: FDG PET imaging of large-vessel vasculitis. PET Clin 7: 227–232, 2012.
© 2012 Lippincott Williams & Wilkins, Inc.